- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375604
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CDK-004 as an intravenous (IV) treatment for advanced hepatocellular carcinoma (HCC), and primary gastric cancer or CRC with secondary liver metastases.
CDK-004 is an investigational therapeutic candidate consisting of cell-derived exosomes loaded with a synthetic lipid-tagged oligonucleotide.
CDK-004 is designed to allow for specific delivery of the STAT6 anti-sense oligonucleotide (ASO) to the myloid to repolarize macrophage from immune suppressive M2 to proinflammatory M1 phenotype, with a potential for meaningful single agent antitumor activity which has not been observed with other pathway inhibitors to date.
CDK-004 will be administered as a single agent intravenously (IV) at various doses.
Dose limiting toxicities (DLTs) will be assessed during the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ying Su, MD, PhD
- Phone Number: 617 865 9936
- Email: Ying.Su@codiakbio.com
Study Contact Backup
- Name: David Mauro, MD, PhD
- Phone Number: 617 949 4205
- Email: David.Mauro@codiakbio.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Must have one of the following cancer types:
- Advanced HCC defined as Barcelona Clinic Liver Cancer (BCLC) Stage B/C not amenable to resection or locoregional therapy;
- Histologic or radiologic proof of liver metastasis from primary CRC which is unresectable with no evidence of extrahepatic metastasis;
- Histologic or radiologic proof of liver metastasis from primary gastric cancer which is unresectable with no evidence of extrahepatic metastasis.
- Documented progression after at least 1 line of FDA approved systemic therapy for advanced HCC/gastric cancer/CRC or intolerable/refuse to chemotherapy.
- ≥ 18 years of age at screening.
- Measurable disease by RECIST v1.1.
- Able to provide archival tumor tissue/fresh biopsy prior to study treatment and on-treatment tumor biopsies if considered safe and medically feasible by the Investigator.
- ECOG performance status of 0-2.
- Acceptable liver function
- Acceptable renal function
- Acceptable hematologic status
- Cirrhosis classified as Child-Pugh Class A (applicable only to patients diagnosed with cirrhosis)..
- Women of child-bearing potential agree to use highly effective contraceptive methods and avoid egg donation and preservation during the study treatment and for 6 months after the last dose of study drug.
- Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation and preservation during the study treatment and for 6 months after the last dose of study drug.
Exclusion Criteria:
- Treatment with any systemic or liver-directed anticancer therapy within 3 weeks of the first dose of study drug.
- Uncontrolled partial or complete biliary obstruction.
- Left ventricular ejection fraction (LVEF) < 50% at Screening.
- 12-lead ECG demonstrating QT interval corrected by Fridericia's formula (QTcF) > 480 ms or history of long QTc syndrome.
- Ongoing, clinically significant AEs due to prior anticancer therapies.
- Patients with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the Investigator will not affect patient outcome.
- Known clinically active brain metastases or known carcinomatous meningitis/leptomeningeal disease.
- Known clinically significant infection.
- Known clinically significant cardiac disease, including unstable angina or has had a procedure to address the underlying cause and has experienced angina within 4 weeks prior to Cycle 1 Day 1, acute myocardial infarction within 6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure.
- Known history of human immunodeficiency virus (HIV).
- If history of concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria: patients with detectable hepatitis B surface antigen (HbsAg) or detectable HBV DNA should be managed per local treatment guidelines. Controlled (treated) hepatitis B patients will be allowed if they started treatment at the time of consent and treatment is continued during study participation; patients with hepatitis C and detectable RNA are eligible if antiviral therapy has been completed prior to first administration of study drug. Testing does not need to be conducted at Screening if results from testing within the past 12 months are available.
- History of liver transplant.
- History of immunodeficiency or is receiving chronic systemic steroid therapy
- Poorly controlled diabetes mellitus.
- Active or previously documented autoimmune or inflammatory diseases
- Is currently participating in a study of an investigational therapy or device or has participated and received an investigation therapy or device within 3 weeks of administration of CDK-004.
- Has another physical or mental health disorder that might cause difficulty in obtaining informed consent and/or participation in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental CDK-004
CDK-004 administered as a single agent intravenously (IV) on Days 1 and 15 of Cycles 1 and 2, on Day 1 of every Cycle.
|
ASO-STAT6 exosome administered Intravenously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize the safety and tolerability of CDK-004.
Time Frame: Up to 2 years
|
Incidence of treatment-emergent adverse events as assessed by CTCAE 5.0.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplasms
- Stomach Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Colorectal Neoplasms
- Liver Neoplasms
Other Study ID Numbers
- CDK-004-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma (HCC)
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)China, Singapore
-
Astellas Pharma IncTerminatedAdvanced Hepatocellular Carcinoma (HCC)Korea, Republic of, Belgium, United States, Hong Kong, Singapore, Taiwan, Germany, Spain, France, Italy
-
Sidney Kimmel Cancer Center at Thomas Jefferson...PfizerActive, not recruitingHCC | Advanced Hepatocellular Carcinoma | Liver CancerUnited States
-
Zai Lab (Shanghai) Co., Ltd.TerminatedAdvanced Hepatocellular Carcinoma (HCC)China
-
Zhejiang Haichang Biotech Co., Ltd.Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)
-
Peking University Cancer Hospital & InstituteRecruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)Italy, Poland, Singapore, United States, China, Ukraine
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedAdvanced Hepatocellular Carcinoma (HCC)China
-
Abramson Cancer Center of the University of PennsylvaniaCompletedADVANCED HEPATOCELLULAR CARCINOMA (HCC)United States
Clinical Trials on CDK-004
-
McGill University Health Centre/Research Institute...Université de Montréal; Argos TherapeuticsCompletedAcquired Immunodeficiency Syndrome | HIV SeropositivityCanada
-
Codiak BioSciencesCompletedAdvanced Solid TumorUnited States, United Kingdom
-
Codiak BioSciencesTerminatedCutaneous T-cell Lymphoma (CTCL)United Kingdom
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
BiocadRecruitingSpinal Muscular Atrophy (SMA)Belarus, Russian Federation
-
Genocea Biosciences, Inc.CompletedStreptococcus PneumoniaeUnited States
-
Inmagene LLCRecruiting
-
MapLight TherapeuticsRecruitingAutism Spectrum DisorderUnited States, Australia, Canada
-
Click Therapeutics, Inc.Active, not recruitingPsoriasis | Atopic DermatitisUnited States
-
Cloudbreak Therapeutics, LLCRecruitingPingueculaUnited States